BRNS
Income statement / Annual
Last year (2024), Barinthus Biotherapeutics plc's total revenue was $14.97 M,
an increase of 1,766.46% from the previous year.
In 2024, Barinthus Biotherapeutics plc's net income was -$61.07 M.
See Barinthus Biotherapeutics plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$14.97 M |
$802.00 K |
$44.70 M |
$268.00 K |
$4.82 M |
$6.85 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$14.39 M
|
$29.84 M
|
| Gross Profit |
$14.97 M
|
$802.00 K
|
$44.70 M
|
$268.00 K
|
-$9.57 M
|
-$23.00 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
-1.98
|
-3.36
|
| Research and Development Expenses |
$38.25 M
|
$41.41 M
|
$41.11 M
|
$16.37 M
|
$14.39 M
|
$29.84 M
|
| General & Administrative Expenses |
$29.67 M
|
$39.84 M
|
$6.39 M
|
$25.12 M
|
$10.48 M
|
$2.67 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$29.67 M
|
$39.84 M
|
$6.39 M
|
$25.12 M
|
$10.48 M
|
$2.67 M
|
| Other Expenses |
$15.02 M
|
$3.46 M
|
$1.24 M
|
$4.00 M
|
-$14.39 M
|
-$29.84 M
|
| Operating Expenses |
$82.94 M
|
$84.72 M
|
$48.74 M
|
$45.49 M
|
$10.48 M
|
$2.67 M
|
| Cost And Expenses |
$82.94 M
|
$84.72 M
|
$48.74 M
|
$45.49 M
|
$24.87 M
|
$32.51 M
|
| Interest Income |
$2.68 M
|
$2.88 M
|
$3.10 M
|
$2.00 K
|
$0.00
|
$40.37 K
|
| Interest Expense |
$53.00 K
|
$28.00 K
|
$19.00 K
|
$2.67 M
|
$3.60 M
|
$133.30 K
|
| Depreciation & Amortization |
$5.80 M
|
$5.43 M
|
$4.32 M
|
$602.00 K
|
$208.00 K
|
$167.62 K
|
| EBITDA |
-$55.37 M |
-$71.07 M |
$5.19 M |
-$47.87 M |
-$16.56 M |
-$22.52 M |
| EBITDA Ratio |
-3.7
|
-88.61
|
0.12
|
-178.62
|
-3.43
|
-3.29
|
| Operating Income Ratio |
-4.54
|
-104.63
|
-0.09
|
-168.74
|
-4.16
|
-3.75
|
| Total Other Income/Expenses Net |
$6.74 M
|
$7.39 M
|
$4.89 M
|
-$5.92 M
|
$2.21 M
|
$2.97 M
|
| Income Before Tax |
-$61.23 M
|
-$76.52 M
|
$850.00 K
|
-$51.14 M
|
-$17.84 M
|
-$22.70 M
|
| Income Before Tax Ratio |
-4.09
|
-95.41
|
0.02
|
-190.82
|
-3.7
|
-3.32
|
| Income Tax Expense |
-$44.00 K
|
-$3.08 M
|
-$4.47 M
|
-$28.00 K
|
$95.00 K
|
$0.00
|
| Net Income |
-$61.07 M
|
-$73.35 M
|
$5.34 M
|
-$50.87 M
|
-$17.71 M
|
-$20.73 M
|
| Net Income Ratio |
-4.08
|
-91.46
|
0.12
|
-189.79
|
-3.67
|
-3.03
|
| EPS |
-1.55 |
-1.91 |
0.14 |
-1.37 |
-2.24 |
-436.87 |
| EPS Diluted |
-1.55 |
-1.91 |
0.14 |
-1.37 |
-2.24 |
-436.87 |
| Weighted Average Shares Out |
$39.35 M
|
$38.39 M
|
$37.25 M
|
$37.19 M
|
$7.90 M
|
$7.82 M
|
| Weighted Average Shares Out Diluted |
$39.35 M
|
$38.39 M
|
$38.17 M
|
$37.19 M
|
$7.90 M
|
$7.82 M
|
| Link |
|
|
|
|
|
|
